LogicFlo AI raises $2.7 Million in seed round led by Lightspeed

New Delhi: LogicFlo AI, a Boston-based AI platform designed specifically for the life sciences sector, has raised $2.7 million in a seed round led by Lightspeed, with participation from leading healthcare and enterprise AI investors.

The funding will support LogicFlo AI’s global expansion across pharmaceutical, biotech, and medtech organizations, and enable deeper deployment with global clients, including a Fortune 500 company already under contract.

Founded by Udith Vaidyanathan and Arun Ramakrishnan, the company is redefining how regulated scientific work is done by replacing fragmented tools and repetitive processes with intelligent AI agents that work under human guidance. Across regulatory affairs, medical writing, quality assurance, and medical information teams, LogicFlo AI enables experts to complete high-compliance workflows in a fraction of the time, without sacrificing accuracy or oversight.

The platform is already in production across several global life sciences companies, with early deployments showing transformative results: medical writing timelines reduced from weeks to minutes, and medical information response times cut from nearly two weeks to just two days. With growing demand and expanding agent libraries, LogicFlo AI is emerging as a foundational layer for regulated enterprises, redefining how complex scientific knowledge work is executed at scale.

Udith Vaidyanathan, LogicFlo AI’s co-founder and CEO, talking about the platform said, “We are at a once-in-a-generation inflection point. For the first time, AI agents are capable enough to drive meaningful productivity gains in regulated scientific work, not just possible, but inevitable. While the rest of the world is focused on automation, instead of people, we are building automation for people. LogicFlo AI puts experts firmly at the center. The goal is to empower the brightest people in life sciences do what only they can do – drive medical science forward and help elevate the standard of care.”

“Traditional automation has failed life sciences because it’s too rigid, too brittle, and too out of touch with how people actually work,” explained Arun Ramakrishnan, LogicFlo AI’s co-founder and CTO. “LogicFlo AI agents are different. They’re intelligent, composable, production-ready, and they understand the nuance of scientific work.”

Rohil Bagga, VP Investments, Lightspeed, said, “We’re thrilled to back LogicFlo AI as they revolutionize how life sciences and biotech organizations operate. Their AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity. Founders Udith and Arun combine deep domain expertise with exceptional technical acumen—we’re excited to support them as they drive transformation in one of the world’s most critical industries.”

With the new funding, LogicFlo AI will accelerate product development, expand integrations with life sciences systems like Veeva and IQVIA, and grow its go-to-market and technical teams to meet rising industry demand. The company’s broader vision is to redefine how scientific work happens, empowering every expert with tools that match the speed and complexity of modern science.